Fingolimod treatment at ART initiation delays SIV rebound after ART interruption

• M. Pino,
• C. King,
• I. Shim,
• H. Wang,
• K. Nguyen,
• S. Samer,
• J. Harper,
• J. Lifson,
• A. Reynaldi,
• C. Deleage,
• K. Padhan,
• B. Cervasi,
• M.P. Davenport,
• C. Petrovas,
• M.M. Lederman,
• M. Paiardini

Affiliations

M. Pino

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

C. King

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

I. Shim

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

H. Wang

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

K. Nguyen

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

S. Samer

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

J. Harper

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

J. Lifson

Leidos Biomedical Research, Frederick, MD, USA

A. Reynaldi

Kirby Institute, UNSW Sydney, Sidney, Australia

C. Deleage

Leidos Biomedical Research, Frederick, MD, USA

K. Padhan

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

B. Cervasi

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA

M.P. Davenport

Kirby Institute, UNSW Sydney, Sidney, Australia

C. Petrovas

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

M.M. Lederman

Case Western Reserve University, Cleveland, OH, USA

M. Paiardini

Yerkes National Primate Research Center, Microbiology and Immunology, Emory University, Atlanta, GA, USA; Emory School of Medicine, Atlanta, GA, USA